Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation

Health Technology Assessment : HTA
C KnightV Abbott

Abstract

To determine the clinical and cost-effectiveness of adding rituximab to the CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy regime for adult patients with diffuse large B-cell lymphoma (DLBCL). Electronic bibliographic database. Comparative studies were selected for review if they addressed the clinical or cost-effectiveness of adding rituximab to CHOP in people aged at least 18 years with DLBCL. The internal validity of the study was assessed through the use of the validated Jadad scoring system. Data were abstracted into standardised data extraction forms. Costs were estimated through resource use data taken from the published trial and the unpublished sponsor submission. Unit costs were taken from published sources, where available. An economic evaluation was undertaken to evaluate the cost-effectiveness of R-CHOP compared with CHOP alone for patients with DLBCL using data sources and methodology similar to the manufacturer's submission. In the systematic review of effectiveness, one randomised controlled trial was identified. The study was, in most respects, methodologically rigorous and well conducted and the statistical evidence favoured the addition of rituximab to CHOP. The total cost of rit...Continue Reading

Citations

Jul 13, 2013·Applied Health Economics and Health Policy·Ebenezer Tetteh, Stephen Morris
Jun 12, 2013·Annals of Hematology·Luciane Pereira LindenmeyerPaula Stoll
Jun 6, 2013·International Journal of Clinical Pharmacy·Vanessa HegeleLuciane Pereira Lindenmeyer
Aug 1, 2007·Expert Review of Pharmacoeconomics & Outcomes Research·Christopher Knight, Fiona Maciver
Mar 13, 2016·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Han-I WangRussell Patmore
Apr 15, 2014·Einstein·Roberta Ismael Lacerda MachadoEutilia Andrade Medeiros Freire
Jan 24, 2007·Cancer Treatment Reviews·Matthew C CheungUNKNOWN Members of the Hematology, Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care
May 1, 2005·Expert Review of Clinical Immunology·Robert M SharkeyDavid M Goldenberg
Aug 24, 2006·Expert Review of Anticancer Therapy·Gerhard HeldMichael Pfreundschuh
Jan 18, 2020·Journal of Interpersonal Violence·N Suzanne FalconerLucie Dale Cluver
May 23, 2012·PharmacoEconomics·Philipp W P AuweilerAndreas Gerber
May 25, 2012·The New England Journal of Medicine·David G Maloney
Jul 25, 2008·Clinical Lymphoma & Myeloma·Swati AndhavarapuGeetha R Nair
Apr 18, 2009·Respiratory Medicine·Stephanie C MansonCarlos Fernandez Vidaurre

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.